Published in Neuropsychiatr Dis Treat on April 08, 2009
Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci (2014) 0.78
Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats. PLoS One (2014) 0.75
Liver Illness and Psychiatric Patients. Hepat Mon (2016) 0.75
Desvenlafaxine. Indian J Psychiatry (2010) 0.75
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 44.03
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83
Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet (2007) 15.96
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry (2001) 4.33
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry (1998) 3.27
Descriptive epidemiology of major depression in Canada. Can J Psychiatry (2006) 2.20
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Quantitative rating of depressive states. Acta Psychiatr Scand (1975) 2.00
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry (2007) 1.93
Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) (2007) 1.47
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin (2008) 1.41
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther (2006) 1.41
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol (2008) 1.36
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol (2008) 1.34
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry (2007) 1.29
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci (2006) 1.28
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol (2007) 1.20
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol (2007) 1.18
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol (2008) 1.14
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry (2007) 1.12
Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin (2009) 1.08
Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull (2008) 0.98
Desvenlafaxine succinate monohydrate. Acta Crystallogr C (2008) 0.96
Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology (2006) 0.94
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos (2008) 0.88
Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol (2008) 0.85
Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause (2008) 0.82
Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord (2003) 0.82
Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res (2006) 0.82
Desvenlafaxine succinate for major depressive disorder. Drugs Today (Barc) (2008) 0.79
Desvenlafaxine: another "me too" drug? Ann Pharmacother (2008) 0.77
Desvenlafaxine succinate for the treatment of major depressive disorder. Expert Opin Pharmacother (2008) 0.77
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord (2005) 4.94
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg (2011) 3.30
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry (2011) 2.23
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 2.17
Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs (2015) 2.07
Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis (2011) 1.77
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord (2009) 1.64
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry (2008) 1.61
Neural stimulation successfully treats depression in patients with prior ablative cingulotomy. Am J Psychiatry (2008) 1.49
Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord (2008) 1.49
Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry (2007) 1.46
A novel examination of atypical major depressive disorder based on attachment theory. J Clin Psychiatry (2009) 1.45
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord (2006) 1.43
Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ (2005) 1.42
The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf (2006) 1.37
Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? J Psychiatry Neurosci (2005) 1.35
Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry (2003) 1.30
A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. J Clin Psychiatry (2012) 1.30
Neuromodulation for treatment-refractory major depressive disorder. CMAJ (2013) 1.29
State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge. Biol Psychiatry (2003) 1.28
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ (2005) 1.25
Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry (2005) 1.22
Real-World Data on SSRI Antidepressant Side Effects. Psychiatry (Edgmont) (2009) 1.21
Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv (2006) 1.17
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord (2009) 1.17
Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci (2009) 1.16
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord (2009) 1.14
The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache (2006) 1.13
Are antidepressants as effective as claimed? Yes, but.... Can J Psychiatry (2007) 1.11
Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry (2008) 1.10
Dimensional personality traits and treatment outcome in patients with major depressive disorder. J Affect Disord (2007) 1.10
Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry (2006) 1.09
Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother (2006) 1.08
The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol Psychiatry (2004) 1.07
Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry (2007) 1.06
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry (2002) 1.03
The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs (2010) 0.99
Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry (2007) 0.98
The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry (2004) 0.98
The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol (2008) 0.97
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord (2002) 0.97
Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. J Nerv Ment Dis (2008) 0.96
Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. J Consult Clin Psychol (2012) 0.96
Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med (2010) 0.95
Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. Br J Psychiatry (2013) 0.94
The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med (2012) 0.93
Validation of an IVRS version of the MADRS. J Psychiatr Res (2005) 0.92
The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf (2006) 0.91
Anxiety disorders and bipolar disorder: a review. Bipolar Disord (2006) 0.91
The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology (2009) 0.91
Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry (2014) 0.89
Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. Depress Anxiety (2014) 0.89
Calculated bioavailable testosterone levels and depression in middle-aged men. Psychoneuroendocrinology (2006) 0.89
Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother (2007) 0.89
Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res (2012) 0.89
Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther (2010) 0.88
Deep brain stimulation for treatment-resistant depression: a psychiatric perspective. Curr Psychiatry Rep (2006) 0.88
Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry (2004) 0.88
Sex differences in hormonal responses to a social stressor in chronic major depression. Psychoneuroendocrinology (2009) 0.88
Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord (2003) 0.87
Role of estrogen in the treatment of depression. Am J Ther (2002) 0.87
A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol (2003) 0.87
Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation. Int Rev Psychiatry (2011) 0.87
Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. Prim Care Companion J Clin Psychiatry (2010) 0.86
Instruments to measure sexual dysfunction in community and psychiatric populations. J Psychosom Res (2010) 0.86
Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Res (2007) 0.86
Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry (2002) 0.85
The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. Int J Psychiatry Med (2012) 0.85
Harm avoidance as a mediator of treatment response to antidepressant treatment of patients with major depression. Psychother Psychosom (2010) 0.85
Low-dose dexamethasone challenge in women with atypical major depression: pilot study. J Psychiatry Neurosci (2002) 0.84
Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry (2015) 0.84
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. J Affect Disord (2013) 0.83
Neuroimaging approaches in mood disorders: technique and clinical implications. Ann Clin Psychiatry (2007) 0.83
Problem gambling in bipolar disorder: results from the Canadian Community Health Survey. J Affect Disord (2007) 0.83
A dimensional approach to personality in atypical depression. Psychiatry Res (2005) 0.83
A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord (2012) 0.82
Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord (2011) 0.81
The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Adv Ther (2010) 0.81
Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep (2011) 0.81
The relationship between childhood abuse and suicidality in adult bipolar disorder. Violence Vict (2008) 0.80
The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol (2011) 0.80
Improving outcomes in depression: a focus on somatic symptoms. J Psychosom Res (2006) 0.80
Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother (2009) 0.80
Association between the Malnutrition-Inflammation Score and depressive symptoms in kidney transplanted patients. Gen Hosp Psychiatry (2011) 0.79
Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol (2003) 0.79
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol (2013) 0.79
Admixture analysis of age at onset in major depressive disorder. Gen Hosp Psychiatry (2012) 0.79
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disord (2013) 0.79
The keys to improving depression outcomes. Eur Neuropsychopharmacol (2011) 0.79
Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinic. Ann Clin Psychiatry (2007) 0.79
Emerging drugs for major depressive disorder: an update. Expert Opin Emerg Drugs (2012) 0.79
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin Investig Drugs (2008) 0.79
The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol (2013) 0.79
Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Curr Med Res Opin (2010) 0.79
Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci (2013) 0.78
The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol (2004) 0.77
Using metaanalysis to evaluate evidence: practical tips and traps. Can J Psychiatry (2005) 0.77